Description
Apatinib Mesylate 0.25g Online
Apatinib Mesylate is used to treat oncology patients suffering from various types of cancer, such as Stomach cancer, Lung cancer, Liver cancer, and Soft tissue sarcoma.
Apatinib Mesylate is a target therapy medication, developed and manufactured in China. In 2014, the results of the randomized phase III clinical trial were presented. The research was held in China. The patients were receiving Apatinib Mesylate as the third line of therapy – a small molecule tyrosine kinase inhibitor that selectively inhibits the vascular endothelial growth factor receptor-2 (VEGFR2). Compared to placebo, the medication has conclusively improved the survival index, with acceptable tolerability levels.
In the clinical trials, Apatinib Mesylate shows promising anti-tumor activity against a wide range of malignant tumor.
The principal investigator from Fudan University, China, presented results of Phase I/II human clinical studies at the 2009 CSCO Meeting (October 17, 2009). Cancer patients were administered varied doses of Apatinib daily for 28 days. Apatinib was well tolerated at doses below 750 mg/day, 3 of 3 dose-limiting toxicities were reported at 1000 mg/day and the maximum tolerated dose is determined to be 850 mg/day. The investigator also reported of 65 cancer patients treated in Phase I/II, 1.54% had a complete response, 12.31% had a partial response, 66.15% had stable disease and 20% had progressive disease. A separate published report on the safety and pharmacokinetics of apatinib in Human clinical studies concludes that it has encouraging antitumor activity across a broad range of cancer types.
Apatinib was first synthesized by Advenchen Laboratories in California, USA, and licensed out global rights to HLB (Korea) in 2020 and is being developed by Jiangsu Hengrui Medicine (China), LSK BioPartners (US), and HLB Life Science (Korea).[2] It is an investigational cancer drug currently undergoing clinical trials as a potential targeted treatment for metastatic gastric carcinoma, metastatic breast cancer, and advanced hepatocellular carcinoma.
